Ggg

1. MEASLES VIRUS
Saroj Kumar Thakur
B.Sc.MLT, M.Sc. Medical Microbiology
(Medical Microbiologist)
Madesh Institute of Health Sciences
(Provincial Hospital)

2. MORPHOLOGY
 Spherical , pleomorphic
 120-250nm size
 Possesses a lipoprotein
envelop having
haemagglutinin(H) spikes but
no neuraminidase activity
 It has fusion protein(F) that
mediated cell fusion &
haemolytic activities.

3. PATHOGENESIS
 Measeles is also known as rubeola
 Highly infectious childhood disease transmitted by
inhalation of virus present in respiratory secretion of
patients
Infects RT----Multiply in RT----Invades blood stream------
spread to RES----Multiply further in RES-----Transported
via blood to epithelial surfaces-skin,mouth,RT &
conjunctva

4. CLINICAL FEATURES
 IP-10-14 days
 Prodromal stage characterised by fever, conjunctivitis,
malaise, running nose & cough
 Koplik’s spot-bright red lesions with a white, central dot on
buccal mucosa are diagnostic
 A few later- a red maculopapular rash appears 1st on the
face & spread downwards. Rash disappears in 3-6 days

5. LABORATORY DIAGNOSIS
 Specimens: Nasopharyngeal swab & blood
 Microscopy: Demonstration of multiple gaint cells in Giemsa-stained
smears of nasal secretions for early diagnosis, even before the rash
appears
 Culture:
 Human or monkey kidney cell culture
 Continuous cell culture (HeLa,VERO)
 Observed for cytopathic effects (CPE

6.  Serological diagnosis
 CFT
 ELISA-IgM
 Neutralization test
 HAI

7. EPIDEMIOLOGY AND PROPHYLAXIS
 Man is the only natural host of measles & monkey
acquires infection from man
 Maximum incidence in children 1-5 years
 Measles is endemic throughout the world & eidemics
usually occurs in later winter & early spring.

8. TREATMENT
 MMR